Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone972-3765-8585
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.80 million
Profitability
Miscellaneous
Employees89
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) posted its quarterly earnings results on Monday, November, 11th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.01. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
1 Wall Street analysts have issued twelve-month price targets for Compugen's shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Compugen's stock price to reach $9.00 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View Analyst Price Targets for Compugen.
What is the consensus analysts' recommendation for Compugen?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.
Has Compugen been receiving favorable news coverage?
News headlines about CGEN stock have trended very positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Compugen earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Compugen.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Alector (ALEC), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), SpringWorks Therapeutics (SWTX), Vericel (VCEL), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), Twist Bioscience (TWST), DBV TECHNOLOGIE/S (DBVT), Cortexyme (CRTX) and Osiris Therapeutics (OSIR).
What other stocks do shareholders of Compugen own?
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, CEO, Pres & Director (Age 52)
- Mr. Ari Krashin, Chief Financial & Operating Officer (Age 46)
- Dr. John J. Hunter Ph.D., Chief Scientific Officer (Age 56)
- Mr. Kirk A. Christoffersen, Sr. VP of Corp. & Bus. Devel. (Age 50)
- Dr. Zurit Levine, Sr. VP of Technology Innovation (Age 51)
Who are Compugen's major shareholders?
Compugen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (15.26%), Taylor Frigon Capital Management LLC (1.46%), Rothschild Investment Corp IL (0.65%), Defender Capital LLC. (0.58%), Benjamin F. Edwards & Company Inc. (0.07%) and Janney Montgomery Scott LLC (0.03%).
Which institutional investors are selling Compugen stock?
CGEN stock was sold by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc., Rothschild Investment Corp IL, Taylor Frigon Capital Management LLC and Defender Capital LLC..
Which institutional investors are buying Compugen stock?
CGEN stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc. and Janney Montgomery Scott LLC.
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $5.55.
How big of a company is Compugen?
Compugen has a market capitalization of $284.66 million and generates $17.80 million in revenue each year. The biotechnology company earns $-22,600,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Compugen employs 89 workers across the globe.View Additional Information About Compugen.
What is Compugen's official website?
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
